Indium-111 satumomab pendetide: The first FDA-approved monoclonal antibody for tumor imaging

Journal of Nuclear Medicine Technology

Volumn 26, Issue 3, 1998, Pages 155-163

  Bohdiewicz, Paul J ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Indium 111 OncoScint CR OV; Indium 111 satumomab pendetide; Monoclonal antibody; Radionuclide tumor imaging

Indexed keywords

MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY B.72.3 IN 111; TUMOR ANTIGEN;

ABDOMINAL PAIN; ALLERGIC REACTION; ANGIONEUROTIC EDEMA; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; ASTHENIA; BRADYCARDIA; CANCER MORTALITY; CHILL; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CRYING; DIARRHEA; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; HYPOTHERMIA; INJECTION SITE; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NERVOUSNESS; OVARY CANCER; PRURITUS; RASH; SWEATING; THORAX PAIN; VASODILATATION; VERTIGO;

AGED; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; COLONIC NEOPLASMS; DRUG APPROVAL; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PENTETIC ACID; PREDICTIVE VALUE OF TESTS; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; SAFETY; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0031719666     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Trichopoulos D, Lipworth L, Petridou E, et al. Epidemiology of cancer. In: De Vita V, Hellman S, Rosenberg SA, eds. Cancer, principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven: 1997:231-257.
2. Nabi H Radiolabeled antibodies in clinical nuclear medicine: a technology coming of age. In: Freeman LM. ed Nuclear medicine annual. New York: Raven Press; 1993 1-27.
3. Ozols RF, Schwartz PE, Eifel PJ Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma In: DeVita V, Hellman S, Rosenberg SA, eds. Cancer, principles and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven; 1997 1502-1539.
4. Halpern SE. An overview of radioimmunoimaging. In: Maguire RT, Van Nostrand D, eds. Diagnosis of colorectal and ovarian carcinoma: application of immunoscintigraphic technology . New York: Marcel Dekker. Inc.; 1992:1-22.
5. Serafini AN From monoclonal antibodies to peptides and molecular recognition units: an overview. J Nucl Med 1993;34:533-536.
6. Zuckier LS DeNardo GL, Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med 1997;27:10-29.
7. Satumomab pendetide (OncoScint CR/OV)., Kit package insert. Princeton. NJ: Cytogen Corp.: 1995.
8. Krag DN, Clinical utility of immunoscintigraphy in managing ovarian cancer. J Nucl Med 1993;34(suppl 3):545-548.
9. Markowitz A, Saleemi K, Freeman LM. Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma. Clin Nucl Med 1993;18:685-700
10. Bohdiewicz PJ, Scott GC, Jum JE, et al. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences Early observations Clin Nucl Med 1995;20:230-236.
11. Neal CE, Johnson DL, Cornwall VL, et al Quantitative analysis of In-111 satumomab pendetide immunoscintigraphy An aid to visual interpretation of images in patients with suspected carcinomatosis. Clin Nucl Med 1996;21: 638-642.
12. Surwit EA, Childers JM, Krag DN, et al. Clinical assessment of In-111-CYT-103 immunoscintigraphy in ovarian cancer Gynecologic Oncology 1993;48: 285-292.
13. Doerr RJ, Abdel-Nabi H, Krag D, et al. Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study. Ann Surg 1991;214:118-124.
14. 111Insatumomab pendetide in patients with colorectal adenocarcinoma: performance and impact on clinical management Dis Colon Rectum 1994;37:129-137.
15. 111In-CYT-103 scanning in recurrent colorectal cancer-does it affect standard management? Dis Colon Rectum 1996;39:514-519.